SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGraft Polymer PLC Regulatory News (GPL)

  • There is currently no data for GPL

Corporate Presentation

20 Mar 2023 07:00

RNS Number : 4426T
Graft Polymer (UK) PLC
20 March 2023
 

20 March 2023

Graft Polymer (UK) Plc

 

("Graft Polymer", the "Company", and together with its subsidiaries, the "Group")

 

New Corporate Presentation   

Graft Polymer (UK) Plc (LSE: GPL), a business focused on the development and commercial production of polymer modification, biological supplements, and nano-drug delivery systems, is pleased to announce that an updated corporate presentation is now available on its website: https://graftpolymer.com/.

**ENDS**

 

For more information, please visit    https://www.graftpolymer.com   or contact:

 

Graft Polymer (UK) Plc

via St Brides Partners

Roby Zomer, Chairman

Yifat Steuer, CFO

Turner Pope Investments (Broker)

+44 20 3657 0050

James Pope

Andy Thacker

St Brides Partners (Public Relations)

Catherine Leftley

graftpolymer@stbridespartners.co.uk

Ana Ribeiro

Max Bennett

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAJLMRTMTABBTJ
12
Date   Source Headline
14th Jan 20257:00 amRNSChange of Name to Solvonis Therapeutics plc
6th Jan 20252:27 pmRNSResult of General Meeting and change of name
16th Dec 20247:00 amRNSProposed acquisition of Awakn Life Sciences Corp
11th Dec 20247:00 amRNSInitial Results University of Nottingham
3rd Dec 20249:44 amRNSNotice of GM and proposed name change
15th Oct 20247:00 amRNSResearch Agreement
4th Oct 20247:00 amRNSResearch and development update
26th Sep 20247:00 amRNSDirectorate Change and grant of options
13th Sep 20247:00 amRNSHalf-year Report
28th Aug 20247:00 amRNSCommercial Collaboration Progress Update
13th Aug 20247:00 amRNSHolding(s) in Company
12th Aug 202410:21 amRNSDirectorate Change
8th Aug 202410:08 amRNSHolding(s) in Company
1st Aug 20247:00 amRNSDirectorate Change
31st Jul 20245:00 pmRNSTotal Voting Rights
23rd Jul 20241:59 pmRNSHolding(s) in Company
23rd Jul 20247:00 amRNSCommercial Collaboration
18th Jul 20247:00 amRNSCommercial Collaboration
17th Jul 20249:28 amRNSHolding(s) in Company
15th Jul 20247:00 amRNSDirectorate Change
12th Jul 20247:00 amRNSHolding(s) in Company
12th Jul 20247:00 amRNSHolding(s) in Company
11th Jul 20249:36 amRNSHolding(s) in Company
11th Jul 20249:27 amRNSHolding(s) in Company
11th Jul 20249:26 amRNSHolding(s) in Company
11th Jul 20249:20 amRNSHolding(s) in Company
11th Jul 20249:20 amRNSHolding(s) in Company
11th Jul 20247:00 amRNSPatent Filings
10th Jul 20244:24 pmRNSHolding(s) in Company
10th Jul 20248:10 amRNSAdmission & Director/PDMR Shareholding
3rd Jul 20242:29 pmRNSPublication of a Prospectus
28th Jun 202412:58 pmRNSResult of AGM
7th Jun 20247:00 amRNSBusiness Update
4th Jun 20244:26 pmRNSNotice of AGM
31st May 20247:00 amRNSPatent Application
28th May 20247:00 amRNSRegulatory Application
9th May 20247:00 amRNSUpdate on recent developments
7th May 20247:00 amRNSGrant of Haemostatic Hydrogel Patent
3rd May 20247:00 amRNSDivestment of Graft Polymer d.o.o – Slo facility
2nd May 20247:00 amRNSReplacement of Chief Executive Officer
30th Apr 20245:05 pmRNSAnnual Financial Report
23rd Apr 20244:17 pmRNSLoan facility update
15th Mar 20247:00 amRNSChairman & Directorate Change & Financial Update
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSGM Statement
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSDirector/PDMR Shareholding
8th Jan 20245:00 pmRNSHolding(s) in Company
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.